Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare VLC vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vanguard MSCI Australian Large Companies Index ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard MSCI Australian Large Companies Index ETF (VLC) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

VLC

CURE

Popularity

Low

Low

Pearlers invested

52

78

Median incremental investment

$1,000.00

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$2,062.06

$1,274.70

Average age group

> 35

> 35


Key Summary

VLC

CURE

Strategy

VLC.AX was created on 2011-05-23 by Vanguard. The fund's investment portfolio concentrates primarily on large cap equity. To closely track the MSCI Australian Shares Large Cap Index, the Fund will hold all of the securities in the index.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

BHP Group Ltd. (17.50 %)

Commonwealth Bank of Australia (13.40 %)

CSL Ltd. (9.73 %)

Natera Inc (2.73 %)

Alnylam Pharmaceuticals Inc (2.65 %)

Vertex Pharmaceuticals Inc (2.64 %)

Top 3 industries

Financials (36.62 %)

Materials (25.30 %)

Health Care (9.73 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

Australia (100.00 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.2 %

0.45 %


Key Summary

VLC

CURE

Issuer

Vanguard

Global X

Tracking index

MSCI Australian Shares Large Cap Index - AUD

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.2 %

0.45 %

Price

$79.31

$42.49

Size

N/A

$28.994 million

10Y return

18.64 %

N/A

Annual distribution yield (5Y)

6.92 %

4.24 %

Market

ASX

ASX

First listed date

26/05/2011

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

VLC

CURE

Popularity

Low

Low

Pearlers invested

52

78

Median incremental investment

$1,000.00

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$2,062.06

$1,274.70

Average age group

> 35

> 35


Pros and Cons

VLC

CURE

Pros

  • Higher exposure to AU market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

  • Higher exposure to US market

Cons

  • Lower exposure to US market

  • Lower exposure to AU market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

VLC

CURE

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Higher distribution yield

Lower distribution yield